1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Apontis Pharma AG

Apontis Pharma AG

APPH.DE
Apontis Pharma AGDE flagDeutsche Börse
11.00
EUR
- -
- -
91.63MMarket Cap
Apontis Pharma AG
APPH.DE
(Deutsche Börse)

Recent

price

11.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
FRC
- -
4.71
4.62
6.02
6.56
4.35
5.82
Revenue per Share
- -
-0.28
-0.14
-0.09
0.32
-1.33
0.09
Basic EPS, GAAP
- -
-0.15
0.08
0.21
0.91
-1.87
-0.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.25
-0.39
0.52
0.84
-0.49
-0.41
Book Value per Share
- -
-1.3
-1.33
3.06
2.99
1.5
1.6
Tangible Book Value per Share
- -
8
8
8
8
8
8
Basic Weighted Avg Shares
- -
40
39
51
56
37
48
Sales/Revenue/Turnover
- -
-5.6
-1.56
3.26
6.84
-40.9
2.61
Operating Margin (%)
- -
1
2
2
2
2
2
Depreciation Expense
- -
-2
-1
-1
3
-11
1
Net Income, GAAP
- -
- -
- -
399.55
29.76
- -
34.62
Effective Tax Rate (%)
- -
-5.98
-3.01
-1.46
4.82
-30.58
1.55
Profit Margin (%)
1
-3
-5
35
38
25
19
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
7
5
3
41
42
30
31
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
-344.04
47.11
- -
-109.1
Return on Capital (%)
- -
- -
- -
- -
46.52
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
205.84%
2.49%
Free Cash Flow
- -
-9.08%
-66.95%
Net Income, GAAP
- -
-235.08%
-106.67%
Sales/Revenue/Turnover
- -
6.95%
31.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
37
2024
- -
- -
- -
- -
48
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.33
2024
- -
- -
- -
- -
0.09
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
Poko Innovations Inc. (POKO.CN)
DURECT Corporation (DRRX)
Lotus Ventures Inc. (LTTSF)
Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ)
City View Green Holdings Inc. (CVGRF)
Business
Apontis Pharma AG is a German pharmaceutical entity specializing in the creation, promotion, and distribution of medical compounds for internal medicine, particularly focusing on fixed-dose combination drugs known as Single Pills. The company’s primary emphasis lies in addressing cardiovascular conditions, including hypertension, hyperlipidemia, and secondary prevention, while also marketing products for respiratory illnesses and diabetes through various collaborations. Founded in 1946 and based in Monheim am Rhein, Germany, Apontis Pharma strives to enhance patient adherence and treatment outcomes through its innovative single-tablet therapies. Following a voluntary public purchase offer, Apontis Pharma became a subsidiary of Zentiva AG in late 2024, with Zentiva securing a controlling interest. A merger squeeze-out procedure was initiated in 2025, anticipating a delisting from the public market.